글로벌 포도막염 약물 시장 – 2028년까지의 산업 동향 및 예측

포도막염 약물 시장의 시장 분석 및 통찰력

Data Bridge Market Research는 포도막염 약물이 2021-2028년 예측 기간 동안 약 5.67%의 CAGR을 보일 것이라고 분석했습니다. 환자 건강에 대한 우려 증가, 만성 질환 유병률 증가, 개인 가처분 소득 증가, 글로벌 의료 지출 증가, 제약 연구의 기술적 발전은 포도막염 약물 시장 성장에 기여하는 주요 요인 중 일부입니다.

포도막염은 눈의 질병입니다. 포도막 주변 부위가 부어 오르고 손상되는 눈의 염증입니다. 포도막의 눈 벽은 홍채 , 맥락막, 섬모체로 구성되어 있습니다. 또한 렌즈, 망막, 시신경과 같은 다른 눈 부위에도 영향을 미칩니다.

전방 포도막염의 유병률 증가는 포도막염 약물 시장의 성장을 뒷받침하고 있습니다. 노령 인구의 증가와 개인의 가처분 소득의 증가도 시장 성장을 촉진하고 있습니다. 또한, 분자 생물학의 발전은 수익성 있는 시장 성장 기회를 창출할 것입니다.

그러나 포도막염 치료와 관련된 부작용은 시장 성장에 큰 도전이 될 것입니다. 저개발 경제권의 적절한 의료 인프라 부족과 개발도상국의 건강 보험 부족은 시장 성장률을 더욱 떨어뜨릴 것입니다.

This uveitis drug market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on uveitis drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Uveitis Drug Market Scope and Market Size

The uveitis drug market is segmented on the basis of cause, type, mechanism of action type, drug type, route of administration and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• Based on the cause, the uveitis drug market has been segmented into infectious uveitis and non-infectious uveitis.
• Based on the type, the uveitis drug market has been segmented into anterior uveitis, intermediate uveitis, posterior uveitis and panuveitis.
• On the basis of mechanism of action type, the uveitis drug market is segmented into corticosteroids, immunomodulators, calcineurin inhibitors, antimetabolites, alkylating agents, T-cell inhibitors, anti-microbials, NSAIDs and intracameral tissue plasminogen activator (TPA).
• On the basis of drug type, the uveitis drug market is segmented into bethamethasone, dexamethasone, prednisolone, cortisone, methotrexate, azathioprine, and mycophenolate mofetil, bevacizumab, tacrolimus, cyclophosphamide and adalimumab.
• On the basis of route of administration, the uveitis drug market is segmented into topical, oral, intravenous, subcutaneous, intramuscular, intravitreal and others.
• On the basis of end users, the market is segmented into hospitals, homecare, specialty clinics, drug stores and others.

Core Uveitis Drug Market Country Level Analysis

The uveitis drug market is analysed and market size insights and trends are provided by country, cause, type, mechanism of action type, drug type, route of administration and end users as referenced above.

The countries covered in the uveitis drug market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the uveitis drug market owing to the prevalence of sophisticated healthcare infrastructure, prevalence of major key players and rapid adoption of new and better healthcare technologies. Asia-Pacific on the other hand is projected to score highest growth rate for the forecast period owing to rising expenditure to develop healthcare infrastructure coupled with rising prevalence of uveitis in this region.

The country section of the uveitis drug market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Uveitis drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Uveitis Drug Market Share Analysis

The uveitis drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to core uveitis drug market.

포도막염 약물 시장 보고서에서 다루는 주요 기업으로는 GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Novartis AG, Astrazeneca, Pfizer Inc., AbbVie Inc., Allergan, Johnson & Johnson Services, Inc., Pfizer Inc., XOMA Corporation., EyePoint Pharmaceuticals, Enzo Biochem Inc., Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceuticals Inc., HanAll Biopharma., DAIICHI SANKYO COMPANY, LIMITED., Alphamab Co. Ltd, Coherus BioSciences, Captisol, Clearside Biomedical, Inc. 등이 있으며, 국내 및 글로벌 기업도 있습니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA), 남미에 대해 각각 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-41182